Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding
September 19, 2024 01:15 ET
|
Basilea Pharmaceutica AG, Allschwil
Initial funding of USD 29 million to support development of Basilea’s clinical stage first-in-class antifungals, fosmanogepix and BAL2062Multi-year Other Transaction Agreement (OTA) allows for...
Correction: Tonner Drones Convenes GM and Expands Strategy
September 19, 2024 01:15 ET
|
Tonner Drones
Tonner Drones Convenes GM and Expands Strategy Cannes, 18 September 2024 18:00, Tonner Drones (the “Company”) is pleased to announce that it is convening a shareholders’ general meeting to...
OKX Explorer Now Supports DuckChain
September 19, 2024 01:05 ET
|
OKX
SINGAPORE, Sept. 19, 2024 (GLOBE NEWSWIRE) -- OKX Explorer, a leading blockchain search engine and Web3 analytics platform, has issued updates for September 19, 2024. OKX Explorer Now Supports...
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit
September 19, 2024 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a...
Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
September 19, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household membersThis is the first time that any antiviral used in the treatment...
Start of Day Message
September 19, 2024 01:00 ET
|
GlobeNewswire, Inc.
LONDON, 19 Sep. 2024 (GLOBE NEWSWIRE) -- This is the Start of Day Message for GlobeNewswire. GlobeNewswire is operated by Notified and is designated by the FCA as an approved primary information...
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
September 19, 2024 01:00 ET
|
argenx SE
ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced...
U.S. grants Vidac Pharma patent offering broad protection of mode of action underlying its oncology drug candidates
September 19, 2024 01:00 ET
|
Vidac Pharma Holding PLC
London (UK), September 19 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class...
Central Iron Ore Limited: Drilling Results Finalised
September 18, 2024 23:28 ET
|
Central Iron Ore Limited
VANCOUVER, British Columbia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Central Iron Ore Limited (CIO – TSX.V) (“CIO” or “the Company”) is pleased to announce this Drilling Update. Central Iron Ore is...
METHODE ELECTRONICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Methode Electronics, Inc. - MEI
September 18, 2024 23:00 ET
|
SkyMedia, LLC
NEW ORLEANS, Sept. 18, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 25, 2024 to file lead plaintiff applications in a...